Clinical Trials in Switzerland / NCT05406063
Recruiting Not applicable

Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases

NCT05406063 · tracked via the Priya Life Science Switzerland tracker
Phase
Not applicable
Started
2022-06-01
Last updated
2025-05-22

Condition(s) studied

Radiation TherapyBone MetastasesPain

Investigational drug(s) / intervention(s)

SBRT

SBRT: Stereotactic multiple fraction radiotherapy

Study summary

To investigate, whether multi-fraction stereotactic body radiation therapy (SBRT) within 3 treatment fractions is non-inferior to the current standard of care of 5 fraction SBRT regarding pain response at 3 months after radiotherapy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Personally signed and dated written informed consent, * Histological diagnosis of malignancy, * Histologically or radiologically diagnosed bone metastasis, * Age ≥ 18 years * Pain or under pain control medication Exclusion Criteria: * Pregnant or lactating women, * Women of childbearing potential or sexually active males not willing to use effective contraception while on treatment and 3 months after the end of treatment, * Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc., * Prior radiotherapy to the intended treatment site, * Lesions \> 5cm in maximum diameter, * Prior treatment with radioactive isotopes within 30 days of randomisation, * Spinal column, hands, feet, or head as intended treatment site,- Fracture at the intended treatment site, * Surgery required or previous surgery at the intended treatment site * Instability of the intended treatment site.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Kantonsspital Winterthur Winterthur Canton of Zurich Recruiting
University Hospital Bern Bern Switzerland Recruiting

More Kantonsspital Winterthur KSW trials in Switzerland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05406063 on ClinicalTrials.gov ↗ ← All trials in Switzerland